{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:51:39Z","timestamp":1753876299620,"version":"3.41.2"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Fabry disease (FD) is an X-chromosome-linked inherited disorder of glycosphingolipid metabolism due to deficient or absent lysosomal \u03b1-galactosidase A activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case summary<\/jats:title>\n                  <jats:p>A 51-year-old Japanese woman with a previous diagnosis of FD presented with pericardial effusion. The exudative pericardial fluid contained globotriaosylsphingosine. Left ventricular hypertrophy progressed despite regular administration of agalsidase alfa every 2 weeks over a 7-year period, with increases in plasma levels of globotriaosylsphingosine and interleukin (IL)-18. In addition, the IL-6 level in the pericardial fluid was markedly higher than that in plasma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>This case suggests that elevated IL-6 and IL-18 levels in pericardial fluid and plasma indicate the severity of FD cardiomyopathy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytab407","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T15:48:59Z","timestamp":1633621739000},"source":"Crossref","is-referenced-by-count":2,"title":["Pericardial effusion in the course of Fabry disease cardiomyopathy: a case report"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9130-109X","authenticated-orcid":false,"given":"Toshihiro","family":"Tsuruda","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Higashi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Saigo Hospital, 29 Saigo-Tashiro, Misato, Higashi-Usuki, Miyazaki 883-1101, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-9044","authenticated-orcid":false,"given":"Toshihiro","family":"Gi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4888-6552","authenticated-orcid":false,"given":"Shoichiro","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kirishima Memorial Hospital, 1-5-19 Fukushima, Kokubu, Kirishima 899-4322, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"key":"2021103110201501700_ytab407-B1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"2021103110201501700_ytab407-B2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson-Fabry disease related cardiomyopathy","volume":"130","author":"Kampmann","year":"2008","journal-title":"Int J Cardiol"},{"key":"2021103110201501700_ytab407-B3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","article-title":"Contribution of inflammatory pathways to Fabry disease pathogenesis","volume":"122","author":"Rozenfeld","year":"2017","journal-title":"Mol Genet Metab"},{"key":"2021103110201501700_ytab407-B4","doi-asserted-by":"crossref","first-page":"87161","DOI":"10.18632\/oncotarget.13552","article-title":"Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4 + 919 G&gt;A mutation","volume":"7","author":"Chien","year":"2016","journal-title":"Oncotarget"},{"key":"2021103110201501700_ytab407-B5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijcard.2005.08.023","article-title":"Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophy","volume":"111","author":"Hoign\u00e9","year":"2006","journal-title":"Int J Cardiol"},{"key":"2021103110201501700_ytab407-B6","doi-asserted-by":"crossref","first-page":"e0127048","DOI":"10.1371\/journal.pone.0127048","article-title":"Nano-LC-MS\/MS for quantification of Lyso-Gb3 and its analogues reveals a useful biomarker for Fabry disease","volume":"10","author":"Sueoka","year":"2015","journal-title":"PLoS One"},{"key":"2021103110201501700_ytab407-B7","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","article-title":"Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings","volume":"57","author":"Devereux","year":"1986","journal-title":"Am J Cardiol"},{"key":"2021103110201501700_ytab407-B8","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur Heart J"},{"key":"2021103110201501700_ytab407-B9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3390\/ijms22031331","article-title":"The cardiovascular phenotype in Fabry disease: new findings in the research field","volume":"22","author":"Sorriento","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2021103110201501700_ytab407-B10","doi-asserted-by":"crossref","first-page":"1221.e1","DOI":"10.1016\/j.cjca.2015.10.033","article-title":"Evaluation of proinflammatory prognostic biomarkers for Fabry cardiomyopathy with enzyme replacement therapy","volume":"32","author":"Chen","year":"2016","journal-title":"Can J Cardiol"},{"key":"2021103110201501700_ytab407-B11","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac involvement in Fabry disease: JACC review topic of the week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2021103110201501700_ytab407-B12","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehs372","article-title":"Management of pericardial effusion","volume":"34","author":"Imazio","year":"2013","journal-title":"Eur Heart J"},{"key":"2021103110201501700_ytab407-B13","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/eurheartj\/eht006","article-title":"Haemodynamically irrelevant pericardial effusion is associated with increased mortality in patients with chronic heart failure","volume":"34","author":"Fr\u00f6hlich","year":"2013","journal-title":"Eur Heart J"},{"key":"2021103110201501700_ytab407-B14","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1002\/pmic.201200317","article-title":"Proteomics analysis of human pericardial fluid","volume":"13","author":"Xiang","year":"2013","journal-title":"Proteomics"},{"key":"2021103110201501700_ytab407-B15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1043-4666(03)00180-7","article-title":"Effect of pericardial fluid pro-inflammatory cytokines on hemodynamic parameters","volume":"23","author":"Ege","year":"2003","journal-title":"Cytokine"},{"key":"2021103110201501700_ytab407-B16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1161\/HYPERTENSIONAHA.109.148635","article-title":"Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats","volume":"56","author":"Mel\u00e9ndez","year":"2010","journal-title":"Hypertension"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytab407\/40523428\/ytab407.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/5\/10\/ytab407\/40883374\/ytab407.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/5\/10\/ytab407\/40883374\/ytab407.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T10:20:32Z","timestamp":1635675632000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytab407\/6383141"}},"subtitle":[],"editor":[{"given":"Elad","family":"Shemesh","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Giacomo Tini","family":"Melato","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Annagrazia","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Matteo","family":"Parollo","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Aiste Monika","family":"Jakstaite","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytab407","relation":{},"ISSN":["2514-2119"],"issn-type":[{"type":"electronic","value":"2514-2119"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,10,1]]},"article-number":"ytab407"}}